Silvia Irina Briganti

Silvia Irina Briganti

Auto-generated profile, based on publicly available information

Silvia Irina Briganti

Division of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2015 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
APAndrea Palermo
Andrea Palermo
RSRocky Strollo
Rocky Strollo
EMErnesto Maddaloni
Ernesto Maddaloni
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
LDLuca D'Onofrio
Luca D'Onofrio
NNNicola Napoli
Nicola Napoli

16 July 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
NNNicola Napoli
Nicola Napoli
RSRocky Strollo
Rocky Strollo
APAngela Paladini
Angela Paladini
SBSilvia I. Briganti
Silvia I. Briganti
PPPaolo Pozzilli
Paolo Pozzilli
SESol Epstein
Sol Epstein
Bone fragility has emerged as a new complication of diabetes. Several mechanisms in diabetes may influence bone homeostasis by impairing the action between osteoblasts, osteoclasts, and osteocytes and/or changing the structural properties of the bone tissue. Some of these mechanisms can potentially alter the fate of mesenchymal stem cells, the initial precursor of the osteoblast. In this review, we describe the main factors that impair bone health in diabetic patients and their clinical impact.

15 January 2021 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
SBSilvia Irina Briganti
Silvia Irina Briganti
ANAnda Mihaela Naciu
Anda Mihaela Naciu
GTGaia Tabacco
Gaia Tabacco
RCRoberto Cesareo
Roberto Cesareo
NNNicola Napoli
Nicola Napoli
APAndrea Palermo
Andrea Palermo
Despite the large number of patients worldwide being on proton pump inhibitors (PPIs) for acid-related gastrointestinal disorders, uncertainty remains over their long-term safety. Particularly, the potential side effects of these drugs on bone health have been evaluated in the last years. The purpose of our narrative review is to gather and discuss results of clinical studies focusing on the interactions between PPIs and fracture risk. Data generated mainly from nested case-control studies and meta-analysis suggest that long-term/high-dose PPIs users are characterized by an increased risk of fragility fractures, mainly hip fractures. However, in these studies, the PPIs-induced bone impairment is often not adjusted for different confounding variables that could potentially affect bone health, and exposure to PPIs was reported using medical prescriptions without adherence evaluation. The mechanisms of the PPI-related bone damage are still unclear, but impaired micronutrients absorption, hypergastrinemia, and increased secretion of histamine may play a role. Clinicians should pay attention when prescribing PPIs to subjects with a preexistent high risk of fractures and consider antiosteoporotic drugs to manage this additive effect on the bone. However, further studies are needed to clarify PPIs action on the bone.

1 December 2014 in Endocrine Practice
Verified
Journal Article
Closed access
APAndrea Palermo
Andrea Palermo
RSRocky Strollo
Rocky Strollo
RPRocco Papalia
Rocco Papalia
LDLuca D'Onofrio
Luca D'Onofrio
EMErnesto Maddaloni
Ernesto Maddaloni
SMSilvia Manfrini
Silvia Manfrini

2 July 2017 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
NNNicola Napoli
Nicola Napoli
RSRocky Strollo
Rocky Strollo
APAngela Paladini
Angela Paladini
SBSilvia I. Briganti
Silvia I. Briganti
PPPaolo Pozzilli
Paolo Pozzilli
SESol Epstein
Sol Epstein
[This corrects the article DOI: 10.1155/2014/690783.].